Digital Asset Focus NovaBay Pharmaceuticals has transitioned its core operations to become an on-chain holding company involved in digital asset ecosystems, presenting opportunities to collaborate on blockchain and cryptocurrency services or infrastructure development.

Recent Financing The company secured significant funding of over 134 million dollars through warrant financing, indicating strong investor confidence and potential for scaling partnerships within digital asset management and protocol participation.

Strategic Partnerships NovaBay has actively partnered with firms like Eyenovia, BioStem, and Sonoma Pharmaceuticals, demonstrating its openness to joint marketing, commercialization, and expansion efforts—potential avenues for co-branded solutions or distribution channels.

Market Expansion With recent moves into European markets for ocular health products and collaborations to promote Avenova-branded products, there is a clear pathway for expanding sales channels and targeting international healthcare providers.

Technology Investments The company's use of blockchain technology and focus on protocol tokens like SKY suggest a need for advanced technological solutions, presenting opportunities to provide blockchain infrastructure, staking platforms, or governance tools to support their ecosystem.